d-loop peptide, synthetic profile

D-loop peptide, synthetic: amino acid sequence given in first source; antigenic peptide which cyclise through a peptide bond between the side chain carboxylic group of Asp10 and the terminal amide of the peptide; designed to mimic an antigenic loop of the haemagglutinin; do not confuse with mitochondrial DNA Displacement loop (D-loop) which is not a protein, but the control region for mtDNA replication [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6449861
MeSH ID	M0211020

Synonyms (9)

Synonym
l-tyrosinamide, l-cysteinyl-l-lysyl-l-arginylglycyl-l-prolylglycyl-l-seryl-l-alpha-aspartyl-l-phenylalanyl-l-alpha-aspartyl-, cyclic (10-1)-peptide
cyclo(cys-lys-arg-gly-pro-gly-ser-asp-phe-asp)tyr, synthetic
130304-73-3
l-cysteinyl-l-lysyl-l-arginylglycyl-l-prolylglycyl-l-seryl-l-alpha-aspartyl-l-phenylalanyl-l-alpha-aspartyl-l-tyrosinamide cyclic (10-1)-peptide
d-loop protein, synthetic
d-loop protein
cyclo(cys-lys-arg-gly-pro-gly-ser-asp-phe-asp)tyr
d-loop peptide, synthetic
(s)-4-(((s)-1-amino-1-oxo-3-phenylpropan-2-yl)amino)-3-((s)-2-((s)-2-((s)-2-(2-((s)-1-(((s,e)-2-((s)-6-amino-2-((r)-2-amino-3-mercaptopropanamido)hexanamido)-5-guanidinopent-3-enoyl)glycyl)pyrrolidine-2-carboxamido)acetamido)-3-hydroxypropanamido)-3-carbo

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (25.00)	18.2507
2000's	5 (62.50)	29.6817
2010's	1 (12.50)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.06 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.36 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.06)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Carcinoma, Squamous Cell of Head and Neck [description not available]	2.11	1
Carcinoma, Epidermoid [description not available]	2.11	1
Cancer of Head [description not available]	2.11	1
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	2.11	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.11	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.11	1
Encephalomyopathies, Mitochondrial [description not available]	2.01	1

d-loop peptide, synthetic

Description